Luisa Politano

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11555374/publications.pdf

Version: 2024-02-01

82 papers	3,585 citations	136950 32 h-index	138484 58 g-index
82 all docs	82 docs citations	82 times ranked	3651 citing authors

#	Article	IF	Citations
1	Role of electrophysiological evaluation for the best device choice to prevent sudden cardiac death in patients with Myotonic Dystrophy Type 1 and Emery Dreifuss Muscular Dystrophy. Trends in Cardiovascular Medicine, 2021, 31, e1-e2.	4.9	6
2	Prevalence of atrial fibrillation in myotonic dystrophy type 1: A systematic review. Neuromuscular Disorders, 2021, 31, 281-290.	0.6	8
3	North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up. PLoS ONE, 2021, 16, e0253882.	2.5	6
4	Read-through approach for stop mutations in Duchenne muscular dystrophy. An update. Acta Myologica, 2021, 40, 43-50.	1.5	3
5	The position of nonsense mutations can predict the phenotype severity: A survey on the DMD gene. PLoS ONE, 2020, 15, e0237803.	2.5	25
6	The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study. Frontiers in Genetics, 2020, 11, 131.	2.3	49
7	Efficacy and safety of ropivacaine HCl in peribulbar anaesthesia for cataract surgery in patients with myotonic dystrophy type 1. Acta Myologica, 2020, 39, 90-93.	1.5	1
8	Giovanni Nigro and the Naples's school: historical contribution to the knowledge of heart involvement in Duchenne/Becker muscular dystrophies. Acta Myologica, 2020, 39, 187-190.	1.5	0
9	SERUM cardiacâ€specific biomarkers and atrial fibrillation in myotonic dystrophy type I. Journal of Cardiovascular Electrophysiology, 2019, 30, 2914-2919.	1.7	3
10	Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS ONE, 2019, 14, e0218683.	2.5	47
11	X-Linked Emeryâ€“Dreifuss Muscular Dystrophy: Study Of X-Chromosome Inactivation and Its Relation with Clinical Phenotypes in Female Carriers. Genes, 2019, 10, 919.	2.4	8
12	Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol. Journal of Medical Genetics, 2019, 56, 293-300.	3.2	30
13	Are there real benefits to implanting cardiac devices in patients with end-stage dilated dystrophinopathic cardiomyopathy? Review of literature and personal results. Acta Myologica, 2019, 38, 1-7.	1.5	7
14	Bachmann bundle pacing reduces atrial electromechanical delay in type 1 myotonic dystrophy patients. Journal of Interventional Cardiac Electrophysiology, 2018, 51, 229-236.	1.3	6
15	Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease. Neuromuscular Disorders, 2018, 28, 586-591.	0.6	24
16	Interatrial block to predict atrial fibrillation in myotonic dystrophy type 1. Neuromuscular Disorders, 2018, 28, 327-333.	0.6	11
17	Interpreting Genetic Variants in Titin in Patients With Muscle Disorders. JAMA Neurology, 2018, 75, 557.	9.0	69
18	ACE inhibition to slow progression of myocardial fibrosis in muscular dystrophies. Trends in Cardiovascular Medicine, 2018, 28, 330-337.	4.9	29

#	Article	IF	Citations
19	Copy Number Variants Account for a Tiny Fraction of Undiagnosed Myopathic Patients. Genes, 2018, 9, 524.	2.4	7
20	Heart transplantation in a patient with Myotonic Dystrophy type 1 and end-stage dilated cardiomyopathy: a short term follow-up. Acta Myologica, 2018, 37, 267-271.	1.5	5
21	Heart transplantation in patients with dystrophinopathic cardiomyopathy: Review of the literature and personal series. Intractable and Rare Diseases Research, 2017, 6, 95-101.	0.9	41
22	Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions. Acta Myologica, 2017, 36, 19-24.	1.5	4
23	Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study. PLoS ONE, 2016, 11, e0151445.	2.5	32
24	Managing dystrophinopathic cardiomyopathy. Expert Opinion on Orphan Drugs, 2016, 4, 1159-1178.	0.8	3
25	The genetic basis of undiagnosed muscular dystrophies and myopathies. Neurology, 2016, 87, 71-76.	1.1	92
26	The Role of the Atrial Electromechanical Delay in Predicting Atrial Fibrillation in Myotonic Dystrophy Type 1 Patients. Journal of Cardiovascular Electrophysiology, 2016, 27, 65-72.	1.7	32
27	Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study. Neuromuscular Disorders, 2016, 26, 189-196.	0.6	32
28	Increased heterogeneity of ventricular repolarization in myotonic dystrophy type 1 population. Acta Myologica, 2016, 35, 100-106.	1.5	8
29	Family context in muscular dystrophies: psychosocial aspects and social integration. Acta Myologica, 2016, 35, 96-99.	1.5	5
30	Management of cardiac involvement in muscular dystrophies: paediatric versus adult forms. Acta Myologica, 2016, 35, 128-134.	1.5	8
31	Burden, professional support, and social network in families of children and young adults with muscular dystrophies. Muscle and Nerve, 2015, 52, 13-21.	2.2	35
32	The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases. European Journal of Human Genetics, 2015, 23, 1116-1123.	2.8	63
33	Cardiac Function in Types II and III Spinal Muscular Atrophy: Should We Change Standards of Care?. Neuropediatrics, 2015, 46, 033-036.	0.6	9
34	Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. Neurology, 2015, 84, 1772-1781.	1.1	50
35	Next generation sequencing on patients with LGMD and nonspecific myopathies: Findings associated with ANO5 mutations. Neuromuscular Disorders, 2015, 25, 533-541.	0.6	65
36	Clinical features of patients with dystrophinopathy sharing the 45-55 exon deletion of DMD gene. Acta Myologica, 2015, 34, 9-13.	1.5	34

#	Article	IF	Citations
37	Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes. PLoS ONE, 2014, 9, e108205.	2.5	98
38	Affinity proteomics within rare diseases: a <scp>BIO</scp>â€<scp>NMD</scp> study for blood biomarkers of muscular dystrophies. EMBO Molecular Medicine, 2014, 6, 918-936.	6.9	105
39	6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes. PLoS ONE, 2014, 9, e83400.	2.5	65
40	The 6 Minute Walk Test and Performance of Upper Limb in Ambulant Duchenne Muscular Dystrophy Boys. PLOS Currents, 2014, 6, .	1.4	24
41	Sleep breathing disorders and nocturnal respiratory pattern in patients with glycogenosis type II. Acta Myologica, 2014, 33, 100-3.	1.5	0
42	Far field R-wave sensing in Myotonic Dystrophy type 1: right atrial appendage versus Bachmann's bundle region lead placement. Acta Myologica, 2014, 33, 94-9.	1.5	11
43	Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative study. Acta Myologica, 2014, 33, 136-43.	1.5	24
44	The effect of atrial preference pacing on atrial fibrillation electrophysiological substrate in Myotonic Dystrophy type 1 population. Acta Myologica, 2014, 33, 127-35.	1.5	11
45	Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study. European Journal of Human Genetics, 2013, 21, 630-636.	2.8	39
46	24 Month Longitudinal Data in Ambulant Boys with Duchenne Muscular Dystrophy. PLoS ONE, 2013, 8, e52512.	2.5	99
47	Atrial fibrillation burden in Myotonic Dystrophy type 1 patients implanted with dual chamber pacemaker: the efficacy of the overdrive atrial algorithm at 2 year follow-up. Acta Myologica, 2013, 32, 142-7.	1.5	18
48	Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology, 2012, 79, 159-162.	1.1	81
49	The effect of atrial preference pacing on paroxysmal atrial fibrillation incidence in myotonic dystrophy type 1 patients: a prospective, randomized, single-bind cross-over study. Europace, 2012, 14, 486-489.	1.7	25
50	Cardiac and muscle imaging findings in a family with X-linked Emeryâ€“Dreifuss muscular dystrophy. Neuromuscular Disorders, 2012, 22, 152-158.	0.6	19
51	Rippling muscle disease and facioscapulohumeral dystrophy-like phenotype in a patient carrying a heterozygous CAV3 T78M mutation and a D4Z4 partial deletion: Further evidence for â€œdouble troubleâ€• overlapping syndromes. Neuromuscular Disorders, 2012, 22, 534-540.	0.6	28
52	The empowerment of translational research: lessons from laminopathies. Orphanet Journal of Rare Diseases, 2012, 7, 37.	2.7	7
53	Increased dispersion of ventricular repolarization in emery dreifuss muscular dystrophy patients. Medical Science Monitor, 2012, 18, CR643-CR647.	1.1	34
54	Early onset â€œelectricalâ€•heart failure in myotonic dystrophy type 1 patient: the role of ICD biventricular pacing. Anatolian Journal of Cardiology, 2012, 12, 517-9.	0.4	22

#	Article	IF	Citations
55	Treatment of dystrophinopathic cardiomyopathy: review of the literature and personal results. Acta Myologica, 2012, 31, 24-30.	1.5	35
56	Right atrial preference pacing algorithm in the prevention of paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients: a long term follow-up study. Acta Myologica, 2012, 31, 139-43.	1.5	21
57	Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. Acta Myologica, 2012, 31, 121-5.	1.5	221
58	The heart and cardiac pacing in Steinert disease. Acta Myologica, 2012, 31, 110-6.	1.5	21
59	On a case of respiratory failure due to diaphragmatic paralysis and dilated cardiomyopathy in a patient with nemaline myopathy. Acta Myologica, 2012, 31, 201-3.	1.5	10
60	P-Wave Duration and Dispersion in Patients with Emery-Dreifuss Muscular Dystrophy. Journal of Investigative Medicine, 2011, 59, 1151-1154.	1.6	27
61	Muscular dystrophy with marked Dysferlin deficiency is consistently caused by primary dysferlin gene mutations. European Journal of Human Genetics, 2011, 19, 974-980.	2.8	67
62	Motor Chip: A Comparative Genomic Hybridization Microarray for Copy-Number Mutations in 245 Neuromuscular Disorders. Clinical Chemistry, 2011, 57, 1584-1596.	3.2	48
63	Does Bachmann's bundle pacing prevent atrial fibrillation in myotonic dystrophy type 1 patients? A 12 months follow-up study. Europace, 2010, 12, 1219-1223.	1.7	32
64	Early onset of cardiomyopathy and primary prevention of sudden death in X-linked Emeryâ€“Dreifuss muscular dystrophy. Neuromuscular Disorders, 2010, 20, 174-177.	0.6	27
65	North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2010, 20, 712-716.	0.6	171
66	One Hundred Twenty-One Dystrophin Point Mutations Detected from Stored DNA Samples by Combinatorial Denaturing High-Performance Liquid Chromatography. Journal of Molecular Diagnostics, 2010, 12, 65-73.	2.8	17
67	Right Atrial Appendage Versus Bachmann's Bundle Stimulation: A Twoâ€Year Comparative Study of Electrical Parameters in Myotonic Dystrophy Typeâ€1 Patients. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1191-1196.	1.2	22
68	Risk of Arrhythmias in MYotonic Dystrophy: trial design of the RAMYD study. Journal of Cardiovascular Medicine, 2009, 10, 51-58.	1.5	37
69	Optimal Site for Atrial Lead Implantation in Myotonic Dystrophy Patients: The Role of Bachmann's Bundle Stimulation. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 1463-1466.	1.2	21
70	Log-PCR: A New Tool for Immediate and Cost-Effective Diagnosis of up to 85% of Dystrophin Gene Mutations. Clinical Chemistry, 2008, 54, 973-981.	3.2	27
71	Molecular and muscle pathology in a series of caveolinopathy patients. Human Mutation, 2005, 25, 82-89.	2.5	64
72	Pulsed doppler tissue imaging in dystrophinopathic cardiomyopathy. Journal of the American Society of Echocardiography, 2002, 15, 891-899.	2.8	36

#	Article	IF	Citations
73	Autonomic nervous system imbalance and left ventricular systolic dysfunction as potential candidates for arrhythmogenesis in Becker muscular dystrophy. International Journal of Cardiology, 1997, 59, 275-279.	1.7	38
74	Autosomal recessive limbgirdle muscular dystrophy, LGMD2F, is caused by a mutation in the Î´â€“sarcoglycan gene. Nature Genetics, 1996, 14, 195-198.	21.4	417
75	Development of Cardiomyopathy in Female Carriers of Duchenne and Becker Muscular Dystrophies. JAMA - Journal of the American Medical Association, 1996, 275, 1335.	7.4	179
76	Evaluation of the cardiomyopathy in becker muscular dystrophy. Muscle and Nerve, 1995, 18, 283-291.	2.2	126
77	Dilated Cardiomyopathy of Muscular Dystrophy: A Multifaceted Approach to Management. Seminars in Neurology, 1995, 15, 90-92.	1.4	9
78	SSCP detection of novel mutations in patients with Emery-Dreifuss muscular dystrophy: definition of a small C-terminal region required for emerin function. Human Molecular Genetics, 1995, 4, 2003-2004.	2.9	48
79	Novel small mutations along the DMD/BMD gene associated with different phenotypes. Human Molecular Genetics, 1994, 3, 1907-1908.	2.9	35
80	Mutation of dystrophin gene and cardiomyopathy. Neuromuscular Disorders, 1994, 4, 371-379.	0.6	99
81	Detection of a nonsense mutation in the dystrophin gene by multiple SSCP. Human Molecular Genetics, 1992, 1, 517-520.	2.9	68
82	Prospective study of X-linked progressive muscular dystrophy in campania. Muscle and Nerve, 1983, 6, 253-262.	2.2	95